Our robust, panspecies, multiassay demonstration of Wnt signaling inhibition in response to itraconazole treatment provides a tantalizing glimpse into the potential utility of this FDA-approved drug as adjuvant treatment in CRC for targeting the Wnt pathway, Lgr5-expressing cells, and cell cycle heterogeneity in a molecularly defined subset of CRCs. The gene discussed is LGR5; the disease is colorectal carcinoma.